First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Camille Travert; Pascale Tomasini; Arnaud Jeanson; Laurent Greillier; Fabrice Barlesi

doi:10.21037/tcr.2019.05.20

Editorial Commentary

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Camille Travert, Pascale Tomasini, Arnaud Jeanson, Laurent Greillier, Fabrice Barlesi

Abstract

In these past few years, immune checkpoint inhibitors (ICI) in locally advanced or metastatic non-small cell lung cancer (NSCLC) have fundamentally changed the prognosis for some patients.

Editorial Commentary

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Abstract

Article Options

Download Citation

Share